Accumulating evidence indicates that MTA3 expression is significantly downregulated in TSCC, and its reduced levels are significantly associated with tumor progression and poor prognosis (47–49) (see Table 1, Figure 3). This evidence concerns the gene MTA3 and neoplasm.